exjade (deferasirox) tablet, orally disintegrating
[Novartis Pharmaceuticals Corporation]
Tablets for Oral Suspension
Exjade® (deferasirox) is an iron chelating agent. Exjade tablets for oral suspension contain 125 mg, 250 mg, or 500 mg deferasirox. Deferasirox is designated chemically as 4-[3,5-Bis (2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic acid and its structural formula is
Deferasirox is a white to slightly yellow powder. Its molecular formula is C21H15N3O4 and its molecular weight is 373.4.
Inactive Ingredients: Lactose monohydrate (NF), crospovidone (NF), povidone (K30) (NF), sodium lauryl sulphate (NF), microcrystalline cellulose (NF), silicon dioxide (NF), and magnesium stearate (NF).
Exjade® (deferasirox) is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.
Pharmacodynamic effects tested in an iron balance metabolic study showed that deferasirox (10, 20 and 40 mg/kg per day) was able to induce a mean net iron excretion (0.119, 0.329 and 0.445 mg Fe/kg body weight per day, respectively) within the clinically relevant range (0.1-0.5 mg/kg per day). Iron excretion was predominantly fecal.
The effect of 20 and 40 mg/kg per day of deferasirox on the QT interval was evaluated in a single-dose, double-blind, randomized, placebo- and active-controlled (moxifloxacin 400 mg), parallel group study in 182 healthy male and female volunteers aged 18-65 years. No evidence of prolongation of the QTc interval was observed in this study.
Exjade is absorbed following oral administration with median times to maximum plasma concentration (tmax) of about 1.5 to 4 hours. The Cmax and AUC of deferasirox increase approximately linearly with dose after both single administration and under steady-state conditions. Exposure to deferasirox increased by an accumulation factor of 1.3 to 2.3 after multiple doses. The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
Deferasirox is highly (~99%) protein bound almost exclusively to serum albumin. The percentage of deferasirox confined to the blood cells was 5% in humans. The volume of distribution at steady state (Vss) of deferasirox is 14.37 ± 2.69 L in adults.
Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion. Deconjugation of glucuronidates in the intestine and subsequent reabsorption (enterohepatic recycling) is likely to occur. Deferasirox is mainly glucuronidated by UGT1A1 and to a lesser extent UGT1A3. CYP450-catalyzed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). No evidence for induction or inhibition of enzymes at therapeutic doses has been observed.
Deferasirox and metabolites are primarily (84% of the dose) excreted in the feces. Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose). The mean elimination half-life (t1/2) ranged from 8 to 16 hours following oral administration.
Deferasirox is minimally (8%) excreted via the kidney. Exjade has not been studied in patients with renal impairment. (See PRECAUTIONS, Laboratory Tests, and ADVERSE REACTIONS.)
Deferasirox is principally excreted by glucuronidation and is minimally (8%) metabolized by oxidative cytochrome P450 enzymes. Exjade has not been studied in patients with hepatic impairment. Exjade treatment has been initiated in patients with baseline liver transaminase levels up to 5 times the upper limit of the normal range. The pharmacokinetics of deferasirox were not influenced by such transaminase levels.
Following oral administration of single or multiple doses, systemic exposure of adolescents and children to deferasirox was less than in adult patients. In children <6 years of age, systemic exposure was about 50% lower than in adults. (See PRECAUTIONS, Pediatric Use.) The pharmacokinetics of deferasirox have not been studied in geriatric patients (65 years of age or older).
Females have a moderately lower apparent clearance (by 17.5%) for deferasirox compared to males.
The primary efficacy study, Study 1, was a multicenter, open-label, randomized, active comparator control study to compare Exjade® (deferasirox) and deferoxamine in patients with β-thalassemia and transfusional hemosiderosis. Patients ≥2 years of age were randomized in a 1:1 ratio to receive either oral Exjade at starting doses of 5, 10, 20 or 30 mg/kg once daily or subcutaneous Desferal® (deferoxamine) at starting doses of 20 to 60 mg/kg for at least 5 days per week based on LIC (liver iron concentration) at baseline (2-3, >3-7, >7-14 and >14 mg Fe/g dry weight). Patients randomized to deferoxamine who had LIC values <7 mg Fe/g dry weight were permitted to continue on their prior deferoxamine dose, even though the dose may have been higher than specified in the protocol.
Patients were to have a liver biopsy at baseline and end of study (after 12 months) for LIC. The primary efficacy endpoint was defined as a reduction in LIC of ≥3 mg Fe/g dry weight for baseline values ≥10 mg Fe/g dry weight, reduction of baseline values between 7 and <10 to <7 mg Fe/g dry weight, or maintenance or reduction for baseline values <7 mg Fe/g dry weight.
A total of 586 patients were randomized and treated, 296 with Exjade and 290 with deferoxamine. The mean age was 17.1 years (range, 2-53 years); 52% were females and 88% were Caucasian. The primary efficacy population consisted of 553 patients (Exjade n=276; deferoxamine n=277) who had LIC evaluated at baseline and 12 months or discontinued due to an adverse event. The percentage of patients achieving the primary endpoint was 52.9% for Exjade and 66.4% for deferoxamine. The relative efficacy of Exjade to deferoxamine cannot be determined from this study.
In patients who had an LIC at baseline and at end of study, the mean change in LIC was -2.4 mg Fe/g dry weight in patients treated with Exjade and -2.9 mg Fe/g dry weight in patients treated with deferoxamine.
Reduction of LIC and serum ferritin were observed with Exjade doses of 20 to 30 mg/kg per day. Exjade doses below 20 mg/kg per day failed to provide consistent lowering of LIC and serum ferritin levels (Figure 1). Therefore, a starting dose of 20 mg/kg per day is recommended. (See DOSAGE AND ADMINISTRATION.)
Figure 1. Changes in Liver Iron Concentration and Serum Ferritin Following EXJADE® (5 to 30 mg/kg per day) in Study 1
Study 2 was an open-label, non-comparative trial of efficacy and safety of Exjade given for 1 year to patients with chronic anemias and transfusional hemosiderosis. Similar to Study 1, patients received 5, 10, 20, or 30 mg/kg per day of Exjade based on baseline LIC.
A total of 184 patients were treated in this study: 85 patients with β-thalassemia and 99 patients with other congenital or acquired anemias (myelodysplastic syndromes, n=47; Diamond-Blackfan syndrome, n=30; other, n=22). Nineteen percent of patients were <16 years of age and 16% were ≥65 years of age. There was a reduction in the absolute LIC from baseline to end of study (-4.2 mg Fe/g dry weight).
Study 3 assessed the safety of Exjade in patients with sickle cell disease and transfusional hemosiderosis. Patients were randomized to Exjade at doses of 5, 10, 20, or 30 mg/kg per day or subcutaneous deferoxamine at doses of 20 to 60 mg/kg per day for 5 days per week according to baseline LIC. See ADVERSE REACTIONS section for safety experience with Exjade in patients with sickle cell disease.
Exjade® (deferasirox) is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Use of Exjade® (deferasirox) is contraindicated in patients with hypersensitivity to deferasirox or to any other component of Exjade.
Cases of acute renal failure, some with a fatal outcome, have been reported following the postmarketing use of Exjade® (deferasirox). Most of the fatalities occurred in patients with multiple co-morbidities and who were in advanced stages of their hematological disorders. Particular attention should be given to monitoring serum creatinine in patients who: are at increased risk of complications, have preexisting renal conditions, are elderly, have co-morbid conditions, or are receiving medicinal products that depress renal function.
Serum creatinine should be assessed in duplicate before initiating therapy to establish a reliable pretreatment baseline, due to variations in measurements. Serum creatinine should be monitored monthly thereafter. Patients with additional renal risk factors (see above) should be monitored weekly during the first month after initiation or modification of therapy, and monitored monthly thereafter.
Dose reduction, interruption, or discontinuation should be considered for increases in serum creatinine. If there is a progressive increase in serum creatinine beyond the age-appropriate upper limit of normal, Exjade should be interrupted. Once the creatinine has returned to within the normal range, therapy with Exjade may be reinitiated at a lower dose followed by gradual dose escalation, if the clinical benefit is expected to outweigh potential risks.
For adult patients, the daily dose of Exjade should be reduced by 10 mg/kg if a rise in serum creatinine to >33% above the average of the pretreatment measurements is seen at two consecutive visits, and cannot be attributed to other causes. For pediatric patients, the dose should be reduced by 10 mg/kg if serum creatinine levels rise above the age-appropriate upper limit of normal at two consecutive visits.
In the clinical studies, for increases of serum creatinine on two consecutive measures (>33% in patients >15 years of age or >33% and greater than the age-appropriate upper limit of normal in patients <15 years of age), the daily dose of Exjade was reduced by 10 mg/kg. Patients with baseline serum creatinine above the upper limit of normal were excluded from clinical studies.
Exjade-treated patients experienced dose-dependent increases in serum creatinine. These increases occurred at a greater frequency compared to deferoxamine-treated patients (38% vs. 14%, respectively) in Study 1. Most of the creatinine elevations remained within the normal range.
In clinical studies, urine protein was measured monthly. Intermittent proteinuria (urine protein/creatinine ratio >0.6 mg/mg) occurred in 18.6% of Exjade-treated patients compared to 7.2% of deferoxamine-treated patients in Study 1. Although no patients were discontinued from Exjade in clinical studies up to 1 year due to proteinuria, monthly monitoring is recommended. The mechanism and clinical significance of the proteinuria are uncertain.
There have been postmarketing reports (both spontaneous and from clinical trials) of cytopenias, including agranulocytosis, neutropenia and thrombocytopenia, in patients treated with Exjade. Some of these patients died. The relationship of these episodes to treatment with Exjade is uncertain. Most of these patients had preexisting hematologic disorders that are frequently associated with bone marrow failure. (See ADVERSE REACTIONS.) In line with the standard clinical management of such hematological disorders, blood counts should be monitored regularly. Interruption of treatment with Exjade should be considered in patients who develop unexplained cytopenia. Reintroduction of therapy with Exjade may be considered, once the cause of the cytopenia has been elucidated.
In Study 1, 4 patients discontinued Exjade because of hepatic abnormalities (drug-induced hepatitis in 2 patients and increased serum transaminases in 2 additional patients). There have been postmarketing reports of hepatic failure, some with a fatal outcome, in patients treated with Exjade. Most of these events occurred in patients greater than 55 years of age. Most reports of hepatic failure involved patients with significant comorbidities, including liver cirrhosis and multi-organ failure. Liver function tests should be monitored monthly during Exjade treatment and dose modifications or interruption considered for severe or persistent elevations.
Serious hypersensitivity reactions (such as anaphylaxis and angioedema) have been reported in patients receiving Exjade, with the onset of the reaction occurring in the majority of cases within the first month of treatment (see ADVERSE REACTIONS). If reactions are severe, Exjade should be discontinued and appropriate medical intervention instituted.
Auditory disturbances (high frequency hearing loss, decreased hearing), and ocular disturbances (lens opacities, cataracts, elevations in intraocular pressure, and retinal disorders) have been reported at a frequency of <1% with Exjade therapy in the clinical studies. Auditory and ophthalmic testing (including slit lamp examinations and dilated fundoscopy) are recommended before starting Exjade treatment and thereafter at regular intervals (every 12 months). If disturbances are noted, dose reduction or interruption should be considered.
Skin rashes may occur during Exjade® (deferasirox) treatment. For rashes of mild to moderate severity, Exjade may be continued without dose adjustment, since the rash often resolves spontaneously. In severe cases, Exjade may be interrupted. Reintroduction at a lower dose with escalation may be considered in combination with a short period of oral steroid administration.
Exjade should be taken once daily on an empty stomach at least 30 minutes prior to food, preferably at the same time every day. The tablets should not be chewed or swallowed whole. The tablets should first be completely dispersed in water, orange juice, or apple juice, and the resulting suspension drunk immediately. After swallowing the suspension, any residue should be resuspended in a small volume of the liquid and swallowed.
Patients should be cautioned not to take aluminum-containing antacids and Exjade simultaneously.
Because auditory and ocular disturbances have been reported with Exjade, patients should have auditory and ophthalmic testing before starting Exjade treatment and thereafter at regular intervals. (See WARNINGS, Special Senses.)
Patients experiencing dizziness should exercise caution when driving or operating machinery (see ADVERSE REACTIONS).
Serum ferritin should be measured monthly to assess response to therapy and to evaluate for the possibility of overchelation of iron. If the serum ferritin falls consistently below 500 mcg/L, consideration should be given to temporarily interrupting therapy with Exjade. (See DOSAGE AND ADMINISTRATION.)
In the clinical studies, the correlation coefficient between the serum ferritin and LIC was 0.63. Therefore, changes in serum ferritin levels may not always reliably reflect changes in LIC.
Laboratory monitoring of renal and hepatic function should be performed. (See WARNINGS.)
The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied. Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin. The effect of digoxin on Exjade pharmacokinetics has not been studied.
The concomitant administration of Exjade and vitamin C has not been formally studied. Doses of vitamin C up to 200 mg were allowed in clinical studies without negative consequences.
The interaction of Exjade with hydroxyurea has not been formally studied. No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.
Exjade should not be combined with other iron chelator therapies, as safety of such combinations has not been established.
The bioavailability (AUC) of deferasirox was variably increased when taken with a meal. Deferasirox should be taken on an empty stomach 30 minutes before eating.
Exjade tablets for oral suspension can be dispersed in water, orange juice, or apple juice.
A 104-week oral carcinogenicity study in Wistar rats showed no evidence of carcinogenicity from deferasirox at doses up to 60 mg/kg per day (about 0.48 times the recommended human oral dose based on body surface area). A 26-week oral carcinogenicity study in p53 (+/-) transgenic mice has shown no evidence of carcinogenicity from deferasirox at doses up to 200 mg/kg per day (about 0.81 times the recommended human oral dose based on body surface area) in males and 300 mg/kg per day (about 1.21 times the recommended human oral dose based on body surface area) in females.
Deferasirox was negative in the Ames test and chromosome aberration test with human peripheral blood lymphocytes. It was positive in 1 of 3 in vivo oral rat micronucleus tests.
Deferasirox at oral doses up to 75 mg/kg per day (about 0.6 times the recommended human oral dose based on body surface area) was found to have no adverse effect on fertility and reproductive performance of male and female rats.
Reproduction studies have been performed in pregnant rats at oral doses up to 100 mg/kg per day (about 0.8 times the recommended human oral dose based on body surface area) and in pregnant rabbits at oral doses up to 50 mg/kg per day (about 0.8 times the recommended human oral dose based on body surface area). These studies have revealed no evidence of impaired fertility or harm to the fetus due to deferasirox. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, deferasirox should be used during pregnancy only if clearly needed.
It is not known whether deferasirox is excreted in human milk. Deferasirox and its metabolites were excreted in breast milk of rats following a 10 mg/kg dose (about 0.08 times the recommended human oral dose based on body surface area). Because many drugs are excreted in human milk, caution should be exercised when deferasirox is administered to a nursing woman.
Of the 700 patients who received Exjade during clinical studies, 292 were pediatric patients 2 to <16 years of age with various congenital and acquired anemias, including 52 patients age 2 to <6 years, 121 patients age 6 to <12 years and 119 patients age 12 to <16 years. Seventy percent of these patients had β-thalassemia. Children between the ages of 2 to <6 years have a systemic exposure to Exjade approximately 50% of that of adults (see CLINICAL PHARMACOLOGY). However, the safety and efficacy of Exjade in pediatric patients was similar to that of adult patients, and younger pediatric patients responded similarly to older pediatric patients. The recommended starting dose and dosing modification are the same for children and adults. (See CLINICAL STUDIES, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)
During the 1-year study, the growth and development were within normal limits.
Exjade clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently, or have a different adverse event profile, from younger subjects. Thirty patients ≥65 years of age were included in clinical studies of Exjade. The majority of these patients had myelodysplastic syndrome (MDS) (n=27). In general, caution should be used in elderly patients due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
A total of 700 patients were treated with Exjade® (deferasirox) in premarketing studies lasting for 48 weeks in adult and pediatric patients. These 700 patients included 469 with β-thalassemia, 99 with rare anemias, and 132 with sickle cell disease. Of these patients, 45% were male, 70% were Caucasian and 292 patients were <16 years of age. In the sickle cell disease population, 89% of patients were Black. Four hundred sixty-nine patients (403 β-thalassemia and 66 rare anemias) were entered into extensions of the original clinical protocols. In ongoing extension studies, median durations of treatment were 88 to 205 weeks.
The most frequently occurring adverse events in the therapeutic studies of Exjade were diarrhea, vomiting, nausea, headache, abdominal pain, pyrexia, cough, and increases in serum creatinine. Maintenance of adequate hydration for patients experiencing diarrhea or vomiting is recommended. Gastrointestinal symptoms, increases in serum creatinine, and skin rash were dose related.
Table 1 displays adverse events occurring in >5% of patients in either treatment group in Study 1. Abdominal pain, nausea, vomiting, diarrhea, and skin rashes were the most frequent adverse events reported with a suspected relationship to Exjade.
|Pyrexia||56 (18.9)||69 (23.8)|
|Headache||47 (15.9)||59 (20.3)|
|Abdominal Pain||41 (13.9)||28 (9.7)|
|Cough||41 (13.9)||55 (19.0)|
|Nasopharyngitis||39 (13.2)||42 (14.5)|
|Diarrhea||35 (11.8)||21 (7.2)|
|Creatinine Increased*||33 (11.1)||0 (0)|
|Influenza||32 (10.8)||29 (10.0)|
|Nausea||31 (10.5)||14 (4.8)|
|Pharyngolaryngeal Pain||31 (10.5)||43 (14.8)|
|Vomiting||30 (10.1)||28 (9.7)|
|Respiratory Tract Infection||28 (9.5)||23 (7.9)|
|Bronchitis||27 (9.1)||32 (11.0)|
|Rash||25 (8.4)||9 (3.1)|
|Abdominal Pain Upper||23 (7.8)||15 (5.2)|
|Pharyngitis||23 (7.8)||30 (10.3)|
|Arthralgia||22 (7.4)||14 (4.8)|
|Acute Tonsillitis||19 (6.4)||15 (5.2)|
|Fatigue||18 (6.1)||14 (4.8)|
|Rhinitis||18 (6.1)||22 (7.6)|
|Back Pain||17 (5.7)||32 (11.0)|
|Ear Infection||16 (5.4)||7 (2.4)|
|Urticaria||11 (3.7)||17 (5.9)|
|*Includes ‘blood creatinine increased’ and ‘blood creatinine abnormal’ which were reported as adverse events. Also see Table 2 .|
In Study 1, 113 patients treated with Exjade had increases in serum creatinine >33% above baseline on 2 separate occasions (Table 2). Twenty-five patients required dose reductions. Increases in serum creatinine appeared to be dose related. (See WARNINGS, Renal.) Seventeen patients developed elevations in SGPT/ALT levels >5 times the upper limit of normal at 2 consecutive visits. Two patients had liver biopsy proven drug-induced hepatitis and both discontinued Exjade therapy. (See WARNINGS, Hepatic.) Two additional patients, who did not have elevations in SGPT/ALT >5 times the upper limit of normal, discontinued Exjade because of increased SGPT/ALT. Increases in transaminases did not appear to be dose related.
| Creatinine increase >33% and <ULN at 2
consecutive post-baseline visits
|113 (38.2)||41 ( 14.1)|
| Creatinine increase >33% and >ULN at 2
consecutive post-baseline visits
|7 (2.4)||1 (0.3)|
| SGPT/ALT >5 x ULN at 2 post-baseline
|25 (8.4)||7 (2.4)|
| SGPT/ALT >5 x ULN at 2 consecutive
|17 (5.7)||5 (1.7)|
Adverse events that led to discontinuations included abnormal liver function tests (2 patients) and drug-induced hepatitis (2 patients ), skin rash, glycosuria/proteinuria, Henoch Schönlein purpura, hyperactivity/insomnia, drug fever, and cataract (1 patient each).
In the overall population of 700 patients, uncommon adverse reactions (0.1% to 1%) included gastritis, edema, sleep disorder, pigmentation disorder, dizziness, anxiety, maculopathy, cholelithiasis, pyrexia, fatigue, pharyngolaryngeal pain, early cataract and hearing loss (see PRECAUTIONS). Adverse events which most frequently led to dose interruption or dose adjustment were rash, gastrointestinal disorders, infections, increased serum creatinine, and increased serum transaminases.
The following adverse reactions have been spontaneously reported during post-approval use of Exjade. Because these reactions are reported voluntarily from a population of uncertain size, in which patients may have received concomitant medication, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure.
There have been reports of cytopenias, including agranulocytosis, neutropenia and thrombocytopenia, in patients treated with Exjade. Although most of these patients had preexisting hematologic disorders that are frequently associated with bone marrow failure, a contributory role for Exjade cannot be excluded. Cases of acute renal failure have been reported in the context of severe complications relating to the underlying disease. There have been postmarketing reports of hepatic failure, some with a fatal outcome, in patients treated with Exjade. Most of these events occurred in patients greater than 55 years of age. Most reports of hepatic failure involved patients with significant comorbidities, including liver cirrhosis and multi-organ failure. (See WARNINGS.)
Skin and subcutaneous tissue disorders: leukocytoclastic vasculitis, urticaria.
Immune system disorders: hypersensitivity reactions (including anaphylaxis and angioedema).
Cases of overdose (2-3 times the prescribed dose for several weeks) have been reported. In one case, this resulted in hepatitis which resolved without long-term consequences after a dose interruption. Single doses up to 80 mg/kg/day in iron overloaded β-thalassemic patients have been tolerated with nausea and diarrhea noted. In healthy volunteers, single doses of up to 40 mg/kg/day were tolerated. There is no specific antidote for Exjade. In case of overdose, induce vomiting and gastric lavage.
The decision to remove accumulated iron should be individualized based on anticipated clinical benefit and risks of Exjade therapy. In patients who are in need of iron chelation therapy, it is recommended that therapy with Exjade® (deferasirox) be started when a patient has evidence of chronic iron overload, such as the transfusion of approximately 100 mL/kg of packed red blood cells (approximately 20 units for a 40-kg patient) and a serum ferritin consistently >1000 mcg/L.
The recommended initial daily dose of Exjade is 20 mg/kg body weight.
After commencing initial therapy, it is recommended that serum ferritin be monitored every month and the dose of Exjade adjusted if necessary every 3 to 6 months based on serum ferritin trends. Dose adjustments should be made in steps of 5 or 10 mg/kg and should be tailored to the individual patient’s response and therapeutic goals (maintenance or reduction of body iron burden). If the serum ferritin falls consistently below 500 mcg/L, consideration should be given to temporarily interrupting therapy with Exjade. Doses of Exjade should not exceed 30 mg/kg per day since there is limited experience with doses above this level.
Exjade should be taken once daily on an empty stomach at least 30 minutes before food, preferably at the same time each day. Tablets should not be chewed or swallowed whole. Exjade should not be taken with aluminum-containing antacid products. Doses (mg/kg per day) should be calculated to the nearest whole tablet. Tablets should be completely dispersed by stirring in water, orange juice, or apple juice until a fine suspension is obtained. Doses of <1 g should be dispersed in 3.5 ounces of liquid and doses of ≥1 g in 7.0 ounces of liquid. After swallowing the suspension, any residue should be resuspended in a small volume of liquid and swallowed.
Exjade® (deferasirox) Tablets for Oral Suspension
Off-white, round, flat tablet with beveled edge and imprinted with “J” and “125” on one side and “NVR” on the other.
Bottles of 30 tablets …………………………………………….………………. (NDC 0078-0468-15)
Off-white, round, flat tablet with beveled edge and imprinted with “J” and “250” on one side and “NVR” on the other.
Bottles of 30 tablets …………………………………………….………………. (NDC 0078-0469-15)
Off-white, round, flat tablet with beveled edge and imprinted with “J” and “500” on one side and “NVR” on the other.
Bottles of 30 tablets …………………………………………….………………. (NDC 0078-0470-15)
Store at 25°C (77°F). Excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Protect from moisture.
Novartis Pharma Stein AG
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936
REV: DECEMBER 2007
Data are from FDA and U.S. National Library of Medicine.